MannKind Corp reports results for the quarter ended December 31 - Earnings Summary
26/02/2025 23:30
MannKind Corp MNKD.OQ reported quarterly adjusted earnings of 3 cents per share for the quarter ended December 31, higher than the same quarter last year, when the company reported breakeven earnings per share. The mean expectation of six analysts for the quarter was for earnings of 4 cents per share. Wall Street expected results to range from 3 cents to 5 cents per share. Revenue rose 31.3% to $76.78 million from a year ago; analysts expected $74.99 million. MannKind Corp's reported EPS for the quarter was 3 cents. The company reported quarterly net income of $7.42 million. MannKind Corp shares had fallen by 12.1% this quarter. FORECAST CHANGES The mean earnings estimate of analysts had risen by about 20% in the last three months. In the last 30 days, there have been no earnings estimate revisions by analysts covering the company. RECOMMENDATIONS The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is "buy." Wall Street's median 12-month price target for MannKind Corp is $9.50 This summary was machine generated from LSEG data February 26 at 11:30 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Dec. 31 2024 | 0.04 | 0.03 | Missed |
| Sep. 30 2024 | 0.03 | 0.02 | Missed |
| Jun. 30 2024 | 0.01 | -0.01 | Missed |
| Mar. 31 2024 | 0.03 | 0.04 | Beat |
Recent news on MannKind
See all newsBrief: MannKind Enters Data-Rich Development Period With Completion Of Randomization In Phase 1B Inflo-1 Study And Enrollment Of First Patient In Phase 2 Inflo-2 Trial For Nintedanib Dpi In Patients With Ipf
U.S. STOCKS ON THE MOVE-Dell, Gap, Costco
MannKind rises after FDA approves inhaled insulin for children
US FDA approves MannKind's inhaled insulin for children (updated)
US FDA approves MannKind's inhaled insulin for children